The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

June 11, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In May, the U.S. Food and Drug Administration (FDA) approved denosumab (Prolia) for treating glucocorticoid-induced osteoporosis (GIOP) in adult men and women with a high risk of fracture.1High fracture risk is defined as a history of osteoporotic fracture, multiple risk factors for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. This FDA approval is based on data that showed adult patients receiving glucocorticoids who also received denosumab had greater increases in bone mineral density (BMD) than patients who received risedronate as an active comparator.2

You Might Also Like
  • Denosumab Is Effective for Glucocorticoid-Induced Osteoporosis
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
  • Supplemental Application for Denosumab Goes to FDA
Also By This Author
  • Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density

The study was a phase 3, 12-month primary analysis of a 24-month randomized, double-blind, double-dummy, active-controlled study (N=795). The efficacy and safety of 60 mg subcutaneous denosumab given every six months was compared with 5 mg oral risedronate given once daily. Patients also received at least 7.5 mg/day of oral prednisone (or equivalent). The study included two patient groups. Patients in the glucocorticoid-initiating group were receiving glucocorticoid treatment for less than three months prior to the study and were planning to receive glucocorticoids for at least six months. Patients in the glucocorticoid-continuing group were receiving glucocorticoids for a minimum of three months prior to the study and were planning to receive glucocorticoids for at least six months.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the glucocorticoid-continuing group, denosumab treatment showed a significantly greater lumbar spine BMD increase than the risedronate-treated patients at Year 1 (3.8% vs. 0.8%, respectively). The treatment difference was 2.9% (P<0.001). Additionally, in the glucocorticoid-initiating group, denosumab treatment showed a significantly greater lumbar spine BMD increase vs. risedronate-treated patients at Year 1 (4.4% vs. 2.3%, respectively). The treatment difference was 2.2% (P<0.001). The effects on the lumbar spine BMD were consistent without regard to patient gender, race, geographic region, menopausal status, baseline age, lumbar spine BMD T score and/or glucocorticoid dose within the groups.

During the study, no new safety signals were identified. The most common adverse reactions were back pain, bronchitis, headache and hypertension. Atypical femoral fracture was reported in one denosumab-treated patient. No cases of osteonecrosis of the jaw were reported. Serious infections were reported in 3.9% (n=15) of risedronate-treated patients and 4.3% (n= 17) of denosumab-treated patients. Dermal and epidermal dermal adverse events, such as dermatitis, eczema and rashes, were reported in 4.2% (n=16) of risedronate-treated patients and 3.8% (n=15) of denosumab-treated patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Amgen Inc. News release: FDA approves Prolia (denosumab) for glucocorticoid-induced osteoporosis. 2018 May 15.
  2. Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018 Apr 6. pii: S2213-8587(18)30075-5. [Epub ahead of print]

Pages: 1 2 | Multi-Page

Filed Under: Conditions, Drug Updates Tagged With: denosumab, FDA, Glucocorticoid-Induced Osteoporosis, Osteoporosis, osteoporosis treatments, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • Denosumab Is Effective for Glucocorticoid-Induced Osteoporosis
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
  • Supplemental Application for Denosumab Goes to FDA
  • Glucocorticoid-Induced Osteoporosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.